This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
On April 24, 1967, the single pilot of Soyuz 1, Vladimir Komarov, became the first in-flight spaceflight fatality. The mission was planned to be a three-day test, to include the first Soviet docking with an unpiloted Soyuz 2, but the mission was plagued with problems. Problems began shortly after launch when one solar panel failed to unfold, leading to a shortage of power for the spacecraft's systems. Further problems with the orientation detectors complicated maneuvering the craft. By orbit 13, the automatic stabilisation system was completely dead, and the manual system was only partially effective. The mission was aborted, Soyuz 1 fired its retrorockets and reentered the Earth's atmosphere. During the emergency re-entry, a fault in the landing parachute system caused the primary chute to fail, and the reserve chute became tangled with the drogue chute, causing descent speed to reach as high as 40 m/s (140 km/h; 89 mph). Shortly thereafter, Soyuz 1 impacted the ground 3 km (1.9 mi) west of Karabutak, and was found on fire. The official autopsy states Komarov died of blunt force trauma on impact. In the US during subsequent years, stories began circulating that in his last transmissions Komarov cursed the engineers and flight staff as he descended, or even that he cursed the Soviet leadership, and that these transmissions were received by an NSA listening station near Istanbul. This would contradict Soviet records of the radio transcripts, and historians such as Asif Azam Siddiqi and Robert Pearlman regard these claims to be fabrications.
Sweat is mostly water. A microfluidic model of the eccrine sweat gland provides details on what solutes partition into sweat, their mechanisms of partitioning, and their fluidic transport to the skin surface. Dissolved in the water are trace amounts of minerals, lactic acid, and urea. Although the mineral content varies, some measured concentrations are: sodium (0.9 gram/litre), potassium (0.2 g/L), calcium (0.015 g/L), and magnesium (0.0013 g/L). Relative to the plasma and extracellular fluid, the concentration of Na+ ions is much lower in sweat (≈40 mM in sweat versus ≈150 mM in plasma and extracellular fluid). Initially, within eccrine glands sweat has a high concentration of Na+ ions. In the sweat ducts, the Na+ ions are re-absorbed into tissue by epithelial sodium channels (ENaC) that are located on the apical membrane of epithelial cells that form the duct (see Fig. 9 of the reference). Many other trace elements are also excreted in sweat, again an indication of their concentration is (although measurements can vary fifteenfold) zinc (0.4 milligrams/litre), copper (0.3–0.8 mg/L), iron (1 mg/L), chromium (0.1 mg/L), nickel (0.05 mg/L), and lead (0.05 mg/L). Probably many other less-abundant trace minerals leave the body through sweating with correspondingly lower concentrations. Some exogenous organic compounds make their way into sweat as exemplified by an unidentified odiferous "maple syrup" scented compound in several of the species in the mushroom genus Lactarius. In humans, sweat is hypoosmotic relative to plasma (i.e. less concentrated).
== Start-up == If the raw catalyst is supplied in the form of nickel oxide, it is necessary to reduce it to metallic nickel before it will operate properly. Alternative catalysts do not necessarily need a reduction treatment. Methanizers should not be heated without hydrogen being supplied to them.
Sources: en.wikipedia.org
== Clinical relevance == IGF-2 is sometimes produced in excess in islet cell tumors and non-islet hypoglycemic cell tumors, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. Loss of imprinting of IGF-2 is a common feature in tumors seen in Beckwith-Wiedemann syndrome. As IGF-2 promotes development of fetal pancreatic beta cells, it is believed to be related to some forms of diabetes mellitus. Preeclampsia induces a decrease in methylation level at IGF-2 demethylated region, and this might be among the mechanisms behind the association between intrauterine exposure to preeclampsia and high risk for metabolic diseases in the later life of the infants. In animals it has been shown that toxins such as PCB (polychlorinated biphenyls) affects IGF II expression.
Ranitidine, a medicine for peptic ulcers sold under the name of Zantac, was developed by Allen & Hanburys (then a part of Glaxo Group Research, now GSK), and patented in 1978 (US4128658A, Example 32). Originally, its crystals were all in Form 1, but the batch prepared on April 15, 1980 exhibited a new infrared spectrogram peak at 1045 cm−1, demonstrating that a new crystal had appeared, designated Form 2. Subsequent batches produced more and more Form 2 despite using the same procedure, until Form 1 completely disappeared. The group patented Form 2 in 1985 (US4521431A ) and 1987 (US4672133A). Though it is very difficult to crystallize Form 1 in the presence of seeds of Form 2, if the two forms are already crystallized, then they can coexist indefinitely when mixed together. Later research showed that the two forms consists of different conformers of ranitidine, making this a case of conformational polymorphism. Specifically, the nitroethenediamine moiety of the ranitidine cations is rotated in different directions in the two forms. Also, that moiety is more disordered in Form 2. As the 1978 patent was nearing its 1995 expiration, many generics companies attempted to develop generics using the procedure described in 1978 patent, but they all ended up with Form 2. Some generics companies (such as Novopharm) claimed that Glaxo never produced Form 1, and thus the 1978 patent inherently anticipated Form 2, thus invalidating the 1985 and 1987 patents (since double patenting is invalid).
The men's basketball team has been one of the nation's most successful programs since Lute Olson was hired as head coach in 1983, and is still known as a national powerhouse in Division I men's basketball. Between 1985 and 2009, the team reached the NCAA Tournament 25 consecutive years, which is the third-longest streak in NCAA history, after Kansas, with appearances from 1990–present, North Carolina, with 27 consecutive appearances from 1975 to 2001. The Wildcats have reached the Final Four of the NCAA tournament in 1988, 1994, 1997, 2001, and 2026. In 1997, Arizona defeated the University of Kentucky, the then-defending national champions, to win the NCAA National Championship (NCAA Men's Division I Basketball Championship) by a score of 84–79 overtime; Arizona's first national championship victory. The 1997 championship team became the first and only in NCAA history to defeat three number-one seeds en route to a national title (Kansas, North Carolina, and Kentucky—the North Carolina game being the final game for longtime UNC head coach Dean Smith). Point guard Miles Simon was chosen as 1997 Final Four MVP (Simon was also an assistant coach under Olson from 2005 to 2008). The Cats also boast the third-highest winning percentage in the nation over the last twenty years. Arizona has won a total of 28 regular season conference championships in its program's history, and 6 PAC-12 tournaments. Since 2005, Arizona has produced 17 NBA draft picks. The Wildcats play their home games at the McKale Center in Tucson.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.